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Abstract
Background: Schizophrenia is associated with autonomic dysfunction and this may increase cardiovascular mortality. Past
studies on autonomic modulation of schizophrenic patients focused on inpatients rather than individuals in a community
setting, especially those receiving non-intensive case management (non-ICM). Besides, autonomic modulation and its
association with health-related quality of life (HRQoL) in this population remain unexplored.
Methods: A total of 25 schizophrenic patients treated by non-ICM and 40 healthy volunteers were matched by age, gender
and body mass index; smokers were excluded. Between the two groups, we compared the individuals’ 5 min resting
assessments of heart rate variability and their HRQoL, which was measured using EuroQoL-5D (EQ-5D). Patients with
schizophrenia were assessed for psychopathology using the Positive and Negative Syndrome Scale for Schizophrenia
(PANSS). We examined the relationship between heart rate variability measurements, HRQoL scores, PANSS scores, and
other clinical variables among the schizophrenic patients treated by non-ICM.
Results: Compared to the controls, patients with schizophrenia showed a significant impairment of autonomic modulation
and a worse HRQoL. Cardiovagal dysfunction among the schizophrenic patients could be predicted independently based on
lower educational level and more negative symptoms. Sympathetic predominance was directly associated with
anticholinergics use and EQ-5D using a visual analogue scale (EQ-VAS).
Conclusion: Patients with schizophrenia treated by non-ICM show a significant impairment of their autonomic function and
HRQoL compared to the controls. Since the sympathovagal dysfunction is associated with more negative symptoms or
higher VAS score, the treatment of the negative symptoms as well as the monitoring of HRQoL might help to manage
cardiovascular risk among these individuals. In addition, EQ-VAS scores must be interpreted more cautiously in such a
population.
Citation: Chang L-R, Lin Y-H, Kuo TBJ, Wu Chang H-C, Liu C-M, et al. (2011) Autonomic Modulation and Health-Related Quality of Life among Schizophrenic
Patients Treated with Non-Intensive Case Management. PLoS ONE 6(11): e26378. doi:10.1371/journal.pone.0026378
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received June 29, 2011; Accepted September 26, 2011; Published November 4, 2011
Copyright:  2011 Chang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a Grant (NTUHYL.99N015) from the National Taiwan University Hospital, Yun-Lin Branch, and a grant (NSC 99-2911-I-008-
100) from the National Science Council (Taiwan) and by a grant (100AC-B3) from the Ministry of Education, Aim for the Top University Plan. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cchyang@ym.edu.tw
Introduction
Schizophrenia is a chronic, debilitating mental disorder that
affects approximately 1% of the general population [1]. It is
associated with central autonomic system abnormalities and these
may influence heart rate variability (HRV) [2,3], baroreflex
sensitivity [4], pupillary light reflex [5], and electrodermal activity
[6]. These abnormalities may be associated with a disease-inherent
genetic vulnerability [7]. The psychopathology of schizophrenia
has been found to be associated with decreased vagal modulation
[4,5,8–14] or overactive sympathetic function [6,8,12]. This
autonomic dysfunction might be exacerbated by antipsychotic
use [15,16]. In addition, the lower functioning of patients with
schizophrenia is associated with repressed overall autonomic and
parasympathetic function [10].
Autonomic dysregulation may reduce the adaptability of the
cardiovascular system to changes in the internal or external
environment [15,17–20], and thus increase the risk of life-
threatening arrhythmias [21], myocardial infarction [22], heart
failure [22], and sudden death [23]. Such effects seem to be
associated with the cardiovascular mortality that is found among
patients with schizophrenia [24,25]. In a British community
cohort of 370 patients with schizophrenia, an excess mortality was
noted after 13-years of follow-up. The standardized mortality ratio
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26378(SMR) of patients with schizophrenia was significantly higher than
in the general population, as were the SMRs for circulatory
diseases and undetermined death [24]. The early identification of
autonomic dysfunction in a community population might help
with the provision of interventions that will minimize this
mortality. However, most studies of autonomic modulation among
patients with schizophrenia have focused on non-medicated
[8,10,11,17] or medicated subjects [10,12,15] in an inpatient
setting. Such studies do not reflect the real-life condition of cardiac
autonomic modulation among schizophrenic patients dwelling in
community. The autonomic status of schizophrenic patients in a
community setting might be different from that of patients in an
inpatient setting because of their greater exposure to environmen-
tal risk factors [24].
Schizophrenic patients treated with non-intensive case man-
agement (non-ICM) constitute a significant community population
of schizophrenics in Taiwan. According to the latest Cochrane
review published in 2011 [26], non-ICM involves providing care
at home or places of work with an assertive outreach, a multi-
disciplinary team, and a caseload of over 20 people. Compared
with ICM, with a caseload of less than 20 people, non-ICM is
more feasible in developing countries due to its clinical
effectiveness and lower cost. Non-ICM is usually indicated for
schizophrenic patients who have poor drug compliance, frequent
relapses or repeated hospitalization. Though this approach seems
to be associated with less hospitalization, the autonomic
modulation status of this population remains unexplored.
In addition to the above, the health-related Quality of life
(HRQoL) of patients with schizophrenia is lower than that of the
general population [27,28]. HRQoL is defined as a patient’s self-
reported perception of his or her physical, emotional, mental, and
functional wellbeing [29], and is a significant treatment outcome
measure for patients with schizophrenia [30,31]. Whether there is
an association between HRQoL and HRV has not been explored
in previous studies.
In this study, we compare time-domain and frequency-domain
measures of HRV with assessments of the individual’s HRQoL
between schizophrenic patients treated by non-ICM and healthy
controls. The two groups were matched by age, gender and body
mass index (BMI); individuals using tobacco were excluded from
this study. We further examined the relationship between HRV,
HRQoL, psychopathology and other clinical variables in the
schizophrenia group. We hypothesized that, firstly, the schizo-
phrenia group would have worse HRV and lower HRQoL
compared to the control group and, secondly, the worse HRV in
schizophrenia group could be predicted by HRQoL and
psychopathology.
Materials and Methods
Participants
This study was carried out by the Department of Psychiatry,
National Taiwan University Hospital (NTUH), Yun-Lin Branch,
in Taiwan. The Institutional Review Board of NTUH approved
this study and all participants provided written informed consent.
From Jan 2011 to May 2011, 25 schizophrenic patients were
voluntarily recruited from the non-ICM program of our hospital,
in which a total of 130 patients with severe mental illness were
enrolled. This program is based on an assertive community
treatment model [26] but there is a caseload of more than 20
patients. It includes: (1) two face-to-face sessions per month at
home or at a place of work by a multi-disciplinary team including
trained psychiatrists, psychiatric nurses, and social workers. Each
session averages 30 minutes, (2) complete evaluation of symptoms,
drug side effects and social functioning by the team members
themselves, (3) an emphasis on medication compliance and
persistent attempts to engage with uncooperative clients, i.e. ‘‘an
assertive outreach’’, (4) offering psychoeducation and counseling to
the patient and their family members, (5) the provision of 24 hour
emergency cover, (6) the allowance of patients and their families’
calling the non-ICM team at any time during the week.
40 healthy volunteers were recruited from same local commu-
nity by poster and internet advertisement during the index period.
All clinical data was obtained by a board-certified psychiatrist. For
this study, we only included participants who met the following
criteria: (a) a DSM-IV diagnosis of schizophrenia, or, for the
healthy controls, the absence of DSM-IV disorders; (b) the absence
of comorbid major depressive or manic episodes, mental
retardation, any organic brain syndrome, hypertension, diabetes
mellitus, or other major systemic disease; (c) non-use of tobacco,
alcohol or any illicit substance; (d) the absence of tricyclic
antidepressants, b-blockers, chlorpromazine, or non-psychotropic
medications that are documented to influence heart rate
variability.
Age, sex and BMI were matched between the two groups.
Thereafter, all participants were investigated by carrying out a 5-
minute electrocardiogram (ECG) in the morning (09:00–12:00).
They were instructed to avoid all types of food containing caffeine
or alcohol on the morning of ECG recording. They were then
evaluated using the EuroQoL-5D (EQ-5D) for HRQoL. Patients
with schizophrenia were assessed for psychopathology using the
Positive and Negative Syndrome Scale for Schizophrenia
(PANSS), and the Global Assessment of Functioning (GAF) for
functioning.
Outcome measures
Heart rate variability. The procedure for HRV analysis
was based on the standard method [32] and has been reported
previously [33]. In brief, a lead I ECG was taken for 5 minutes in
the daytime while each subject sat quietly and breathed normally.
ECG signal acquisition, storage and processing were performed
using a HRV analyzer (SS1C, Enjoy Research Inc., Taiwan).
Signals were recorded using an 8-bit analog-to-digital converter
with a sampling rate of 512 Hz. The digitized ECG signals were
analyzed online, and were simultaneously stored on a hard disk for
offline verification. The computer algorithm then identified each
QRS complex and rejected each ventricular premature complex
or noise according to likelihood using a standard QRS template.
Normal and stationary R-R interval values (RR) were resampled
and interpolated at a rate of 7.11 Hz to produce continuity in the
time domain. This interpolation produced 2048 data points over
288 s, which was then used for the subsequent Fourier
transformation.
Power spectral analysis was performed using fast Fourier
transformation (FFT). The baseline shift was deleted, and a
Hamming window was used to attenuate the leakage effect [34].
For each time segment (288 s, 2048 data points), our algorithm
estimated the power spectrum density based on the FFT. The
resulting power spectrum was corrected for attenuation resulting
from the Hamming window. The power spectrum was subse-
quently quantified into the standard frequency-domain measure-
ments as defined previously [32,33], including variance (variance
of RR-interval values), very low-frequency power (VLF, 0.003–
0.04 Hz), LF (0.04–0.15 Hz), HF (0.15–0.40 Hz), total power (TP)
and LF/HF, normalized LF (LF%). LF% was calculated from LF/
(total power-VLF)6100. TP, VLF, LF, HF, and LF/HF were
logarithmically transformed to correct for skewed distributions
[33]. HF is considered to represent vagal control of the heart rate.
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some investigators to reflect sympathetic modulations and to
mirror the sympathovagal balance [32,35,36]. LF was initially
interpreted as a marker of sympathetic modulation but has been
found to reflect baroreflex function in more recent studies [37]. TP
and LF are contributed to jointly by the sympathetic and
parasympathetic nerves [32].
Positive and Negative Syndrome Scale (PANSS). The
severity of psychopathologic symptoms was evaluated with the
Positive and Negative Syndrome Scale (PANSS) [38] by a board-
certified psychiatrist. PANSS includes a positive symptoms
subscale score, a negative symptoms subscale score, and a
general psychopathology score. It is a semi-structured interview
based on information relating to the previous week and includes
30 items and a 1–7 point continuum for each item. Higher scores
reflect a higher severity of psychotic symptoms. Anxiety and
depression scores, i.e. the 2
nd and 6
th item of general
psychopathology, were singled out as independent variables due
to their possibly individual effects on HRV [39,40].
Global Assessment of Functioning (GAF). The objective
evaluation of the patients’ clinical course and social functioning
was based on Global Assessment of Functioning (GAF), which is a
measure of an individual’s overall psychological, social, and
occupational functioning as rated by the clinician [1]. The range
of the GAF score is between 0 and 100. A higher score means
better functioning, while a lower score means poorer functioning.
EuroQoL-5D (EQ-5D). The EQ–5D has five dimensions
with three categories of severity; these dimensions are mobility,
self-care, usual activities, pain/discomfort, and anxiety/depression
(www.euroHRQoL.org). As there is, as yet, no available Chinese
utility value, we adopted the most commonly used EQ–5D UK
population value set. The EQ–5D UK time trade-off index (TTO)
[41] ranges between 1 (full health) and 20.59 (0 is death). A TTO
index is based on hypothetical trade-offs between length of life and
symptoms. Only participants who fully completed the EQ–5D
questionnaire were included. Although there is no unequivocally
agreed threshold for a minimum clinically important change in the
EQ–5D, thresholds of 0.07 points have been observed [42]. The
visual analogue scale (VAS) records the respondent’s self-rated
health on a vertical, visual analogue scale where the endpoints are
labeled with ‘Best imaginable health state’ (indicating 100 points)
and ‘Worst imaginable health state’ (indicating 0 point). EQ-5D
has been validated for assessing patients with schizophrenia [43–
45] and the use of the Chinese version of EQ–5D has also been
validated [46].
Other data collected with the outcome measures included
demographic data (age, education, marital status, occupation),
medical conditions (systolic and diastolic blood pressure, body
mass index (BMI)), clinical variables (onset of illness, duration of
non-ICM, hospitalization times), and current psychotropic med-
ications (second generation antipsychotics (SGA) use, chlorprom-
azine equivalent dose of antipsychotics and the use of benzodi-
azepines, anticholinergics, mood stabilizers, and antidepressants).
Statistical methods
All statistical tests were carried out using the SPSS version 15.0
for Windows (SPSS, Chicago, Ill). Descriptive statistics for the total
sample were analyzed to categorize the patients in terms of clinical
and psychosocial characteristics. The demographic data and blood
pressure among the patient and healthy control groups were
compared by Pearson’s Chi-square (for categorical variables) and
by independent t test (for continuous variables).
To test our first hypothesis, we used independent t test to
compare EQ-5D values, the time-domain measure and frequency-
domain measures of the HRV between the two groups. We used
Pearson correlation coefficients to examine the associations
between identifiably impaired measures of HRV, demographic
data, medication use, psychopathology, functioning, and HRQoL.
Subsequently, multivariate regression analysis with stepwise
method was performed to examine the association between
impaired measures of HRV and HRQoL. To control for the
confounding factors, covariates which have significant correlation
with HRV measures in univariate analysis would be included in
the models. Model 1 contains EQ-VAS only. Other covariates
were added stepwise in the final model. Statistical significance was
assumed for p,0.05. Values are expressed as means 6 standard
deviation (SD).
Results
Demographic data and clinical variables
The demographic and psychopathological characteristics of the
participants are summarized in Table 1. The age of the
schizophrenia group ranged from 23 years to 55 years (mean
age 41.369.2 years) and their illness duration varied from 6 years
to 34 years (mean duration 19.667.9 years). As shown in Table 1,
when matched by age, gender and BMI, patients with schizo-
phrenia were less likely to be married or to be employed than
members of the healthy group. They also had a lower educational
level and had lower blood pressures. Their EQ-VAS scores were
significantly lower than the control group (64.1621.7 vs
79.9611.7, p=0.003).
Comparison of time-domain and frequency-domain
measures between the schizophrenia group and the
control group
As shown in Table 2, patients with schizophrenia had a shorter
RR when compared to the controls. They also had smaller values
for TP (6.8361.19 vs 7.3560.77, p=0.033) and HF (4.4661.57
vs 5.3261.04, p=0.010), which indicated parasympathetic
dysfunction. In contrast, they had higher LF/HF than control
(1.3360.76 vs 0.9460.69, p=0.036), which reflected sympathetic
predominance. However, there was no group difference for LF,
which mirrors baroreflex function.
Correlation analysis of the identifiably impaired measures
of HRV in the schizophrenia group
In order to explore potential correlation with the impaired
measures for HRV in the schizophrenia group, we conducted a
correlation analysis. Table 3 shows the correlations between the
impaired HRV measures (RR, TP, HF, LF/HF) and demographic
data, medication use, psychopathology, functioning, and HRQoL.
Mean RR was correlated with antidepressant use and the negative
symptoms subscale score. Both TP and HF were correlated with
educational level, the negative symptoms subscale score and EQ-
VAS. TP was also correlated with age and length of illness. LF/HF
was correlated with anticholinergics use and EQ-VAS. No
correlations were detected between the impaired measures for
HRV and depression, anxiety or functioning.
Multivariate stepwise regression analysis of the identified
impaired measures for HRV in schizophrenia group
The determinants of each impaired HRV parameter of
schizophrenic patients treated with non-ICM are shown in
table 4. In model 1, which included HRQoL as the only covariate,
EQ-VAS was a significant negative determinant of TP, HF and a
positive determinant for LF/HF. In the final model, EQ-VAS
Autonomic Modulation in Schizophrenia
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p=0.023) after other covariates were adjusted for. In comparison,
the effect of EQ-VAS on TP and HF became insignificant after
adding other covariates into the regression model. Notably, a
borderline statistical significance was noted in the association
between EQ-VAS and HF (b=20.349, p=0.057). TP and HF
were predicted by educational level (b=0.459, 0.509, respectively)
and negative symptoms subscale score of PANSS (b=20.393,
20.356, respectively) independently. Anticholinergics use re-
mained positively associated with LF/HF after controlling for
Table 1. Sample Description.
Schizophrenia group Healthy control Statistics
(N=25) (N=40) t (63) x2 p value
Age, years 41.369.2 41.2612.7 20.036 0.972
Gender, N (%)
Male 10 (40) 19 (48) 0.350 0.554
Female 15 (60) 21 (52)
BMI, kg/m
2 25.064.8 24.762.9 20.302 0.764
Education (%)
College and above 2 (8) 14 (35) 18.766 ,0.001
Senior high school 3 (12) 16 (40)
Junior high school and below 20 (80) 10 (25)
Martial status(%)
Unmarried 15 (60) 13 (33) 14.669 ,0.001
Married or cohabiting 4 (16) 25 (63)
Divorced, separated, or widowed 6 (24) 2 (5)
Job (%) (N=32)
Employed 3 (12) 30 (94) 38.478 ,0.001
Unemployed 22 (88) 2 (6)
Length of illness, years 19.6 (67.9) —
Duration of non-ICM, months 50.8 (645.4) —
Number of hospitalizations 2.6 (62.6) —
Systolic blood pressure, mmHg 117.0 (613.1) 125.2 (614.5) 2.296 0.025
Diastolic blood pressure, mmHg 73.6 (69.2) 81.8 (611.2) 3.072 0.003
Medication, n (%)
Second-generation antipsychotics 18 (72) —
Benzodiazepines 13 (52) —
Anticholinergics 11 (44) —
Antidepressants 4 (16) —
Mood stabilizers 2 (8) —
Chlorpromazine equivalent dose, mg 242.0 (6227.2) —
PANSS scores
Positive symptoms subscale 14.6 (65.3) —
Negative symptoms subscale 17.8 (67.0) —
General psychopathology 27.8 (67.5) —
Total score 60.2 (617.0) —
Anxiety (G2) 2.3 (61.2) —
Depression (G6) 1.6 (60.9) —
CGI-Severity scale 4.0 (61.2) —
GAF 45.2 (67.4) —
EuroQol-5D (N=32)
EQ-TTO 0.85 (60.18) 0.89 (60.22) 0.637 0.527
EQ-VAS 64.1 (621.7) 79.9 (611.7) 3.495 0.003
Note: N refers to the number of cases. Values are means (6Standard Deviation).
PANSS, Positive and Negative Syndrome Scale; BMI, body mass index; GAF, global assessment of functioning; CGI, clinical global impression; EQ-TTO, EuroQoL-5D time-
trade-off score; EQ-VAS, EuroQoL-5D score on visual analogue scale.
doi:10.1371/journal.pone.0026378.t001
Autonomic Modulation in Schizophrenia
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e26378Table 2. Comparisons of heart rate variability measures between the schizophrenia group and the healthy control groups.
Schizophrenia group Healthy control Statistics
(N=25) (N=40) t (63) p value
RR, ms 718.07 (697.60) 790.58 (6115.54) 2.608 0.011
TP, ln (ms
2) 6.83 (61.19) 7.35 (60.77) 2.175 0.033
HF, ln (ms
2) 4.46 (61.57) 5.32 (61.04) 2.661 0.010
LF, ln (ms
2) 5.79 (61.22) 6.26 (60.81) 1.867 0.067
LF/HF, ln (ratio) 1.33 (60.76) 0.94 (60.69) 22.137 0.036
Note: Values are means (6Standard Deviation).
Mean RR, mean of all RR intervals; TP, total power; HF, high-frequency spectral component; LF, low-frequency spectral component of HRV.
doi:10.1371/journal.pone.0026378.t002
Table 3. Univariate correlation of heart rate variability measures in schizophrenia group (N=25).
RR, ms TP, ln(ms
2) HF, ln(ms
2) LF/HF, ln(ratio)
Age, year 0.239 20.411* 20.380 0.123
Gender (Female=0, Male=1) 0.041 0.072 0.030 20.050
Educational level (below junior high school=0, above=1) 0.217 0.493* 0.542** 20.250
Marital status (single, divorced, widowed=0, married, cohabitate=1) 0.009 20.216 20.099 20.259
Job (no=0, yes=1) 0.376 20.026 ,0.001 20.011
BMI, kg/m
2 0.356 20.036 0.014 20.107
Length of illness, years 20.002 20.437* 20.369 0.118
Duration of non-intensive case management, months 20.085 20.225 20.229 0.239
Number of hospitalizations 20.100 0.014 20.030 0.163
Medication
Second generation antipsychotics (No=0, Yes=1) 20.194 0.161 0.156 20.038
Antipsychotic dose (chlorpromazine equivalent dose) 20.305 20.266 20.278 20.031
Benzodiazepines (No=0, Yes=1) 0.207 20.073 20.111 0.104
Anticholinergics (No=0, Yes=1) 0.216 0.037 20.124 0.411*
Antidepressants (No=0, Yes=1) 20.406* 20.174 20.327 0.050
Mood stabilizers (No=0, Yes=1) 0.239 0.213 0.139 20.076
PANSS scores
Positive symptoms subscale 20.226 20.182 20.308 0.150
Negative symptoms subscale 20.474* 20.433* 20.404* 0.184
General psychopathology 20.207 20.250 20.220 20.110
Total score 20.357 20.345 20.359 0.074
Anxiety (G2) 20.352 0.005 0.003 20.054
Depression (G6) 20.336 20.259 20.173 20.214
CGI-Severity scale 20.356 20.018 20.116 0.120
GAF 0.217 0.319 0.374 20.203
EuroQol-5D
EQ-TTO 0.143 0.299 0.306 20.083
EQ-VAS 20.173 20.440* 20.524** 0.444*
Note: RR, mean of all RR intervals; TP, total power; HF, high-frequency spectral component; LF, low-frequency spectral component of HRV.
*p,0.05.
**p,0.01.
***p,0.001.
PANSS, Positive and Negative Syndrome Scale; BMI, body mass index; GAF, global assessment of functioning; CGI, clinical global impression; EQ-TTO, EuroQoL-5D time-
trade-off score; EQ-VAS, EuroQoL-5D score on visual analogue scale.
doi:10.1371/journal.pone.0026378.t003
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were statistically significant with R
2 of 0.263, 0.399, 0.419, and
0.359. There was no significant effect of age, length of illness, or
antidepressants use on HRV parameters in regression models.
Discussion
Although autonomic dysfunction in patients with schizophrenia
has been validated in previous studies, it is much less explored in
patients in community settings, especially those treated by non-
ICM. We also do not know the extent of and the correlations with
autonomic dysfunction in this population. Our study is pilot one in
the field of community psychiatry because we have studied
exclusively autonomic dysfunction and its determinants among
schizophrenic patients who are being treated by non-ICM. We try
to investigate the ‘‘real-world’’ condition of autonomic modulation
among patients dwelling in community, rather than in laborato-
ries. Furthermore, our patient population is special because the
duration of illness is among the longest in HRV studies of
schizophrenia (averagely 19.6 years in our study, versus less than
10 years in most studies) [11–13]. Our result is also pioneering in
exploring the relationship between HRV and HRQoL in patients
with schizophrenia. We have carefully controlled for age, gender,
and BMI, and excluded tobacco use, alcohol use, illicit drug use,
major systemic disease and other psychiatric illnesses for the two
populations. Our findings support the first hypothesis, namely that
schizophrenic patients treated with non-ICM show a significant
impairment of cardiac autonomic modulation and a lower
HRQoL compared to the control individuals. They have a lower
mean RR, an impaired HRV, a repressed parasympathetic
function, and a sympathetic predominance. Our findings only
partially support our second hypothesis. In this context, we were
able to show that the reduced vagal function was associated with
severer psychopathology of negative symptoms; HRQoL, as
indicated by EQ-VAS, was associated with sympathetic predom-
inance.
As expected, total autonomic activity, parasympathetic function
and sympathovagal balance, as indicated by TP, HF and LF/HF,
were found to be worse in the schizophrenia group compared to
the control group. This supports previous findings [4–6,8–12].
These patterns of autonomic dysfunction persists even when
patients with schizophrenia are treated with antipsychotics
[10,15,16]. Our results are also consistent with this finding.
Williams and colleagues proposed that patients with paranoid
schizophrenia have impairment of their higher centers within the
central autonomic network (CAN) in addition to the presence of
peripheral autonomic dysfunction. Lack of activation in the medial
prefrontal cortex compromises inhibitory control over amygdale-
driven autonomic function [47]. The subsequent autonomic
dysfunction possibly causes recurrent arrhythmia or sudden
cardiac death in patients with schizophrenia [11,48,49]. Monitor-
ing such cardiovascular dysfunction might be beneficial to patients
with schizophrenia and help to reduce cardiovascular mortality.
Our results indicated the association between vagal activity and
negative symptoms. Impaired vagal function has previously been
found to be related to more pronounced positive symptoms
[11,13,19] or to the total score of PANSS [14,19,20]. However, we
found the correlation between TP, HF and negative symptom
subscale score. This correlation remained significant after
controlling for potential confounders in multiple regression
models. The relationship between HRV and negative symptoms
has been much less reported [13]. In a population of acutely ill
schizophrenic patients, Boettger and colleagues [13] found the
correlation between HRV and positive symptoms. They also
noticed a significant correlation between negative symptoms and
PD
mHF (mean high frequency peak decay), a novel non-linear
measure representing vagal information flow. The correlation was
positive during the day (r=0.457), which was consistent with our
result since higher PD
mHF values represented lower vagal
information flow. Interestingly, this correlation turned to be
negative during the night (r=20.467), which reflected altered
diurnal autonomic variation [13]. Negative symptoms include
affective flattening, poverty of thoughts, and avolition [1]. They
may be affected by CAN, which regulates affective, cognitive and
motivational processes in the brain [2,3].Whether this exclusive
association between negative symptom and vagal activity in our
Table 4. Multiple linear regression models predicting heart rate variability measures in schizophrenia group (N=25).
Predictors RR, ms TP, ln (ms
2) HF, ln (ms
2) LF/HF, ln (ratio)
Model 1: R
2 0.030 0.194* 0.274** 0.197*
b (B6S.E.)
EQ-VAS 20.173 20.440* (20.025±0.011) 20.524** (20.039±0.013) 0.444* (0.016±0.007)
Final Model: R
2 0.263* 0.399** 0.419** 0.359**
b (B6S.E.)
EQ-VAS 20.148 20.270 20.349 0.430* (0.015±0.006)
Age 0.173 20.336 20.262 20.145
Educational level 0.197 0.459* (1.340±0.496) 0.509** (1.967±0.646) 0.042
Length of illness 0.063 20.218 20.102 20.138
PANSS-Negative symptoms subscale 20.513* (27.048±2.515) 20.393* (20.067±0.029) 20.356* (20.080±0.038) 0.196
Anticholinergics 0.138 0.118 20.036 0.403* (0.623±0.270)
Antidepressants 20.283 0.037 20.137 0.028
Note: RR, mean of all RR intervals; TP, total power; HF, high-frequency spectral component; LF, low-frequency spectral component of HRV.
*p,0.05.
**p,0.01.
***p,0.001.
B: unstandardized coefficient; b: standardized coefficient; S.E.: standard error; PANSS, Positive and Negative Syndrome Scale; EQ-VAS, EuroQoL-5D score on visual
analogue scale.
doi:10.1371/journal.pone.0026378.t004
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to 20 years averagely) remained speculative. We still have very
little understanding of this relationship as well as diurnal
regulation between negative symptom and vagal function. Its
neurophysiological mechanism needs further investigation.
In univariate analysis, we found that TP, HF, and LF/HF were
all correlated with EQ-VAS. After controlling for demographic
data, psychopathology and medication, only the association
between LF/HF and EQ-VAS remained. The statistical signifi-
cance of the relationship between TP, HF, and EQ-VAS became
marginal. The relationship between impaired cardiac autonomic
function and HRQoL in patients with schizophrenia has not been
investigated. In a normal population, self-reported quality of life
and depression might affect HRV [50]. Among patients with
chronic obstructive pulmonary disease, HRV is directly linked to
the perceived quality of life [51]. However, the finding that
schizophrenic patients with more sympathetic predominance
report better well-being went beyond our expectation. The
overestimation of HRQoL by schizophrenic patients might
partially explain this phenomenon. While the EQ-TTO score is
estimated from five dimensions (mobility, self-care, usual activities,
pain or discomfort, and anxiety or depression), the EQ-VAS score
is rated by participants intuitively. The latter assesses well-being in
a highly subjective manner. It is possible that patients with
schizophrenia might have an unrealistic appreciation of self and
the outer world due to cognitive deficits as well as reasoning bias
[52]. Recently, Beck and colleagues [53] found that schizophrenic
patients with deficit syndrome had more defeatist attitudes but
higher self-esteem than those without deficit syndrome. These
attitudes might lead to social withdrawal and protect the self-
esteem. Thus they might report an unrealistically high quality of
life to the community mental health team though they had poor
mental or physical condition actually. Sympathetic predominance
per se, or associated vagal withdrawal, may increase cardiovascular
risk [54,55]. In these circumstances, the potential cardiovascular
risk might be overlooked. The neurophysiological basis for this
association remains unclear. While prefrontal hypoactivity is
related to cognitive deficits in schizophrenia, it may fail to inhibit
subcortical sympathoexcitatory circuits and lead to subsequent
sympathetic predominance [55]. Future research should direct
toward exploring the roles of dysfunctional attitudes and
neurocognition in the relationship between HRV and HRQoL.
Clinicians must be aware that patients may report feeling well, but
they may, nevertheless, have autonomic dysfunction. Careful
monitoring of autonomic status is therefore important among
schizophrenic patients living in community and subjective quality
of life rating measures, especially EQ-VAS, should be interpreted
with caution among this population.
Our study indicated positive association between educational
level and vagal function, which supported previous findings [56].
Patients with higher educational level may lead healthier lifestyle
and have better cognitive capacities, which are related to better
HRV [56,57]. It might be helpful to monitor autonomic function
of patients with lower educational level and to provide them
relevant psychoeducation. Besides, we noticed the positive
association between anticholinergics use and sympathetic predom-
inance. Anticholinergics were mostly reported to reduce parasym-
pathetic function in previous research [58]. In our patients, the
autonomic imbalance in the sympathetic direction was also
accompanied by vagal withdrawal. The use of anticholinergics
should be cautious in patients with schizophrenia since it is
associated with sympathovagal imbalance. Although no correla-
tion between cardiovagal function and antipsychotic use was
identified, antipsychotic use may still exacerbate autonomic
dysfunction [15,16]. The impact of long-term antipsychotic use
on autonomic modulation of chronic patients as well as its
relationship with cardiac toxicity deserve further investigation
[59]. Our results showed no association between the patient’s
functioning and lower measures of HRV, which were different
from Fujibayashi et al. ’s findings [10]. The measure of GAF is
simplified, and more comprehensive evaluation of functionality is
needed to clarify the inconsistent results.
There are several limitations to this study. Firstly, we did not
include evaluations of neuro-cognitive functions, drug compli-
ance, and any side effects of the patient’s medication.
Therefore, there is the possibility that these factors might
influence HRV. Some disease-independent factors, such as
physical fitness and unhealthy lifestyle, may also influence HRV
and are hard to control for [13,60]. For example, aerobic
exercises can increase parasympathetic tone and decrease
sympathetic activity [60]. Secondly, the sample size is limited
due to the need to carefully match for age, gender, and
educational level and to exclude tobacco use and comorbid
conditions. In future research, larger sample size is needed to
validate the preliminary findings of this study. Thirdly, there
were four patients (16%) in our study population taking
antidepressants (two used fluoxetine, two sertraline). Evidences
regarding whether antidepressants deteriorate HRV or not
remains inconclusive, as are seen in most recent large-scale
studies and their consequent debates [39,61–63]. However,
Koschke and colleagues [64] suggested differential autonomic
effects of serotonin and noradrenaline selective reuptake
i n h i b i t o r( S N R I )a sw e l la ss e l e c t i ve serotonin reuptake inhibitor
(SSRI) by novel non-linear techniques. Though we did not find
significant associations between HRV and antidepressant use in
our current sample (Table 4), our results should be interpreted
cautiously. Fourthly, we were unable to evaluate possible
discriminative influences on autonomic function by the various
antipsychotic agents because SGA use and the chlorpromazine
equivalent dose do not represent autonomic effects of different
agents. Fifthly, though the 5-minutes measure of HRV revealed
detailed information about autonomic modulation of RR
intervals [32], it did not have advantages owned by 24-hours
ECG recordings including less mathematical errors, less
influenced by fluctuations of autonomic functions, as well as
assessment of diurnal changes [13]. This is a limitation of our
study. Sixthly, the results of a non-ICM program should not be
generalized to patients in other community settings or
institutions due to differences in the clinical characteristics of
the patients. Up to the present there have been no trials that
compare the clinical characteristics of non-ICM patients with
standard care patients [26]. Thus the lack of a comparison
group receiving standard care precludes direct investigation of
non-ICM characteristics. Finally, our study was cross-sectional
in nature, which means that it is not possible to generate any
conclusions regarding causality between the variables.
As an important treatment model of community mental health,
non-ICM components are as pragmatically necessary as hospital
services in all areas regardless of the level of resources available
[65]. Despite clinical effectiveness, non-ICM is still associated with
significant impairment in HRV and HRQoL when compared with
a healthy population. Since sympathovagal imbalance is associated
with psychopathology of negative symptoms and higher VAS
score, the treatment of negative symptoms as well as the
monitoring of HRQoL might help to manage cardiovascular risk
among these individuals. The subjective rating of EQ-VAS score
should be interpreted cautiously in schizophrenic patients treated
with non-ICM.
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